Edition:
India

Edwards Lifesciences Corp (EW.N)

EW.N on New York Stock Exchange

172.66USD
22 May 2019
Change (% chg)

$0.66 (+0.38%)
Prev Close
$172.00
Open
$171.19
Day's High
$173.94
Day's Low
$171.19
Volume
257,509
Avg. Vol
306,249
52-wk High
$197.30
52-wk Low
$134.38

About

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient's diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan... (more)

Overall

Beta: 0.87
Market Cap(Mil.): $35,862.28
Shares Outstanding(Mil.): 208.50
Dividend: --
Yield (%): --

Financials

Edwards, Medtronic heart valve systems prove worth in low-risk patients: studies

Non-invasive heart valve replacement systems from Medtronic Plc and rival Edwards Lifesciences Corp proved as good or better than open heart surgery in younger, more active patients for whom the surgical option was deemed low risk, according to trial results that had been scheduled to be presented on Sunday.

16 Mar 2019

Edwards, Medtronic heart valve systems prove worth in low-risk patients -studies

Non-invasive heart valve replacement systems from Medtronic Plc and rival Edwards Lifesciences Corp proved as good or better than open heart surgery in younger, more active patients for whom the surgical option was deemed low risk, according to trial results that had been scheduled to be presented on Sunday.

16 Mar 2019

CORRECTED-Edwards, Medtronic heart valve systems prove worth in low-risk patients -studies

March 16 Non-invasive heart valve replacement systems from Medtronic Plc and rival Edwards Lifesciences Corp proved as good or better than open heart surgery in younger, more active patients for whom the surgical option was deemed low risk, according to trial results that had been scheduled to be presented on Sunday.

16 Mar 2019

Edwards Lifesciences beats on revenue but forecast lags estimates

U.S. medical device maker Edwards Lifesciences narrowly topped Wall Street estimates for quarterly revenue on Thursday as it sold more heart monitors, but its outlook for March quarter earnings fell below analysts' forecasts.

01 Feb 2019

Edwards Lifesciences beats on revenue but forecast lags estimates

Jan 31 U.S. medical device maker Edwards Lifesciences narrowly topped Wall Street estimates for quarterly revenue on Thursday as it sold more heart monitors, but its outlook for March quarter earnings fell below analysts' forecasts.

01 Feb 2019

Edward Lifesciences pays Boston Scientific $180 million to end patent row

Edwards Lifesciences Corp has paid rival Boston Scientific Corp $180 million as part of a settlement to end long-standing patent disputes between the two medical device makers.

15 Jan 2019

UPDATE 2-Edward Lifesciences pays Boston Scientific $180 mln to end patent row

Jan 15 Edwards Lifesciences Corp has paid rival Boston Scientific Corp $180 million as part of a settlement to end long-standing patent disputes between the two medical device makers.

15 Jan 2019

Earnings vs. Estimates